Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India
- First Posted Date
- 2010-09-30
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1386
- Registration Number
- NCT01212133
- Locations
- 🇮🇳
Novo Nordisk Investigational Site, Bangalore, India
First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- InflammationHealthyRheumatoid Arthritis
- Interventions
- Drug: NNC0114-0000-0005Drug: placebo
- First Posted Date
- 2010-09-24
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 64
- Registration Number
- NCT01208506
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
Phase 2
Terminated
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- Drug: placebo
- First Posted Date
- 2010-09-21
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3
- Registration Number
- NCT01206101
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom
Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
Phase 1
Completed
- Conditions
- Haemophilia ACongenital Bleeding Disorder
- Interventions
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 27
- Registration Number
- NCT01205724
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom
Comparison of Two Identical NN1250 Formulations in Healthy Volunteers
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 26
- Registration Number
- NCT01193387
Observational Study of NovoPen Echo® on Safety and Treatment Satisfaction in Children and Adolescents With Type 1 Diabetes
Completed
- Conditions
- Delivery SystemsDiabetesDiabetes Mellitus, Type 1
- Interventions
- Device: NovoPen Echo®
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 358
- Registration Number
- NCT01180530
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Malmö, Sweden
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: placebo
- First Posted Date
- 2010-08-10
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 9341
- Registration Number
- NCT01179048
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, West Midlands, United Kingdom
A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2010-08-03
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 28
- Registration Number
- NCT01174303
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2010-08-02
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 27
- Registration Number
- NCT01173926
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2010-07-20
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 401
- Registration Number
- NCT01165684
- Locations
- 🇸🇮
Novo Nordisk Investigational Site, Trbovlje, Slovenia
© Copyright 2025. All Rights Reserved by MedPath